BKM Wealth Management LLC Reduces Stock Position in Smith & Nephew SNATS, Inc. $SNN

BKM Wealth Management LLC reduced its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 5.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,753 shares of the medical equipment provider’s stock after selling 1,238 shares during the period. BKM Wealth Management LLC’s holdings in Smith & Nephew SNATS were worth $636,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Hexagon Capital Partners LLC lifted its holdings in Smith & Nephew SNATS by 63.3% in the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 406 shares during the period. Richards Merrill & Peterson Inc. lifted its holdings in Smith & Nephew SNATS by 500.0% in the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 1,000 shares during the period. Bessemer Group Inc. lifted its holdings in Smith & Nephew SNATS by 3,471.4% in the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider’s stock worth $49,000 after buying an additional 1,701 shares during the period. Banque Transatlantique SA purchased a new position in shares of Smith & Nephew SNATS during the first quarter valued at approximately $52,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Smith & Nephew SNATS by 22.4% during the first quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider’s stock valued at $103,000 after purchasing an additional 666 shares during the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on SNN shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, October 8th. Canaccord Genuity Group lifted their target price on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a “hold” rating in a report on Monday, August 18th. Wall Street Zen lowered shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Friday, October 3rd. Finally, Sanford C. Bernstein set a $37.50 target price on shares of Smith & Nephew SNATS and gave the company a “market perform” rating in a report on Tuesday. Eight research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $36.75.

Smith & Nephew SNATS Price Performance

Shares of SNN opened at $36.35 on Friday. The company has a market capitalization of $15.51 billion, a P/E ratio of 16.83, a price-to-earnings-growth ratio of 0.99 and a beta of 0.69. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. The firm has a 50 day moving average of $36.71 and a 200 day moving average of $31.73. Smith & Nephew SNATS, Inc. has a twelve month low of $23.69 and a twelve month high of $38.79.

Smith & Nephew SNATS Cuts Dividend

The company also recently declared a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be given a dividend of $0.285 per share. The ex-dividend date of this dividend is Friday, October 3rd. This represents a dividend yield of 165.0%. Smith & Nephew SNATS’s dividend payout ratio (DPR) is 26.39%.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.